Psychosocial effects of neurofibromatosis type 2 (Part 1): General effects

Audiological Medicine

Volumn 4, Issue 4, 2006, Pages 202-210

  Neary, Wanda J ^a   Stephens, Dafydd ^b   Ramsden, Richard T ^c   Evans, Gareth ^d  

^a Guardian House ^*  (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Employment; Neurofibromatosis 2; Psychosocial effects; Relationships; Semi structured questioning

Indexed keywords

ARTICLE; COMMUNICATION DISORDER; DISEASE SEVERITY; EMPLOYMENT; FAMILY RELATION; HEARING IMPAIRMENT; HUMAN; NEUROFIBROMATOSIS; PRIORITY JOURNAL; SEMI STRUCTURED INTERVIEW; SOCIAL PSYCHOLOGY;

EID: 34848916574     PISSN: 1651386X     EISSN: 16513835     Source Type: Journal    
DOI: 10.1080/16513860601113809     Document Type: Article

References (14)

1. Rouleau GA, Wertelecki W, Haines JL, Hobbs WJ, Trofatter JA, Seizinger BR, et al. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature. 1987;329:246-8.
2. Barker V, Wright E, Nguyen K, Cannon L, Fain P, Goldgar D, et al. Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science. 1987;236:1100-2.
3. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Teare D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. 1. Prevalence, mutation rate, fitness and confirmation of maternal transmission effect on severity. J Med Genet. 1992;29:841-6.
4. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84,304:603-18.
5. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994;52:450-61.
6. Mautner VF, Lindenau M, Baser ME, Hazim W, Tatagiba M, Haase W, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurg. 1996;38:881-5.
7. Evans DGR, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Archs Disease Childhood. 1999;81:496-9.
8. Neary W, Stephens D, Ramsden R, Evans G. Psychosocial aspects of neurofibromatosis type 2 reported by affected individuals. In: Stephens D, Jones L, editors. The effects of genetic hearing impairment in the family. Chichester: Wiley; 2006. p. 207-26.
9. Neary W, Stephens D, Ramsden R, Evans G. Psychosocial aspects of neurofibromatosis type 2 reported by relatives/significant others. In: Stephens D, Jones L, editors. The effects of genetic hearing impairment in the family. Chichester: Wiley; 2006. p. 227-36.
10. Neary WJ, Newton VE, Vidler M, Ramsden RT, Lye RH, Dutton JEM, et al. A clinical, genetic and audiological study of patients and families with bilateral acoustic neurofibromatosis. J Laryngol Otol. 1993;107:6-11.
11. World Health Organization. International Classification of Functioning, Disability and Health-ICF. Geneva, World Health Organization, 2001.
12. Barcham LJ, Stephens SDG. The use of an open-ended problems questionnaire in auditory rehabilitation. Br J Audiol. 1980;14:49-54.
13. Bateman N, Nikolopoulos TP, Robinson K, O'Donoghue GM. Impairments, disabilities, and handicaps after acoustic neuroma surgery. Clin Otolaryngol. 2000;25:62-5.
14. Bem C, Lee C, Dawson R, Watkinson J. Is Clinical Otolaryngology publishing patient - centred research? Clin Otolaryngol. 2004;29:84-93.